Omri Amirav-Drory
VCGeneral Partner, NFX Bio, NFX
Scientist-founder investing in frontier techbio
San Francisco, USA$500K–$5M checks2 notable investments
Pre-SeedSeedSeries A
BioHealthcareDeep TechAI
Background
Omri Amirav-Drory, Ph.D. is General Partner at NFX Bio. He founded Genome Compiler, which was acquired by Twist Bioscience, and subsequently led Corporate Development at Twist. He was a Founding Partner at Tech.Bio before joining NFX in 2020. He holds a Ph.D. and B.S. in Biochemistry and Molecular Biology from Tel Aviv University and conducted postdoctoral research at Stanford.
Investment Thesis
Backs scientist-CEOs building transformative techbio and synthetic biology companies; believes longevity and bio-AI convergence define the next wave.
Investment Focus
Stages
Pre-SeedSeedSeries A
Typical check: $500K–$5M
Sectors
BioHealthcareDeep TechAI
Based in: San Francisco, USA (North America)
Notable Investments
Last updated: Jun 11, 2026